Clinical Trial Update: Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update exploring the combination of PARP inhibitors with peptide receptor radionuclide therapy for neuroendocrine tumors, currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Snippet

Sponsor: Erasmus Medical Center | Conditions: Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy | Phase 1 | Status: RECRUITING